Meeting
2023 ASCO Annual Meeting
Plasma arginine as a candidate predictive biomarker for response to immune checkpoint inhibition (ICI) in metastatic colorectal cancer (mCRC): Analysis of the CCTG CO.26 trial.
Authors
Lucy Xiaolu Ma
Princess Margaret Cancer Centre, University Health Network, Toronto, ON, Canada
Lucy Xiaolu Ma , Jonathan M. Loree , Derek J. Jonker , Hagen Fritz Kennecke , Scott R. Berry , Felix Couture , Chaudhary E. Ahmad , John R. Goffin , Petr Kavan , Mohammed Harb , Bruce Colwell , Setareh Samimi , Benoit Samson , Tahir Abbas , Nathalie Aucoin , Francine Aubin , Sheryl L. Koski , Dongsheng Tu , Christopher J. O'Callaghan , Eric X Chen
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Gastrointestinal Cancer—Colorectal and Anal
Track
Gastrointestinal Cancer—Colorectal and Anal
Sub Track
Epidemiology/Outcomes
Citation
J Clin Oncol 41, 2023 (suppl 16; abstr 3545)
DOI
10.1200/JCO.2023.41.16_suppl.3545
Abstract #
3545
Poster Bd #
245
Abstract Disclosures
Similar Posters
First Author: Eric Xueyu Chen
Poster
2019 Gastrointestinal Cancers Symposium
CCTG CO.26 trial: A phase II randomized study of durvalumab (D) plus tremelimumab (T) and best supportive care (BSC) versus BSC alone in patients (pts) with advanced refractory colorectal carcinoma (rCRC).
First Author: Eric Xueyu Chen
Poster
2024 ASCO Gastrointestinal Cancers Symposium
Quality-adjusted time without symptoms of disease or toxicity (Q-TWiST) analysis of fruquintinib + best supportive care (BSC) compared with placebo + BSC in metastatic colorectal cancer (mCRC): Results from the FRESCO-2 trial.
First Author: Sebastian Stintzing
Poster
2023 ASCO Annual Meeting
Reversion of RAS mutations in metastatic colorectal cancer in the CCTG CO.26 clinical trial.
First Author: Florence T.H. Wu